Graziano Lolli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6480406/publications.pdf

Version: 2024-02-01

37	1,622	21	36
papers	citations	h-index	g-index
39	39	39	2383
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO Journal, 2008, 27, 1907-1918.	7.8	295
2	Unprecedented Selectivity and Structural Determinants of a New Class of Protein Kinase CK2 Inhibitors in Clinical Trials for the Treatment of Cancer. Biochemistry, 2011, 50, 8478-8488.	2.5	154
3	CAK—Cyclin-Dependent Activating Kinase: A Key Kinase in Cell Cycle Control and a Target for Drugs?. Cell Cycle, 2005, 4, 565-570.	2.6	151
4	Inhibition of Protein Kinase CK2 by Flavonoids and Tyrphostins. A Structural Insight. Biochemistry, 2012, 51, 6097-6107.	2.5	127
5	The Crystal Structure of Human CDK7 and Its Protein Recognition Properties. Structure, 2004, 12, 2067-2079.	3.3	124
6	CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs?. Cell Cycle, 2005, 4, 572-7.	2.6	67
7	Structural Determinants of Protein Kinase CK2 Regulation by Autoinhibitory Polymerization. ACS Chemical Biology, 2012, 7, 1158-1163.	3.4	58
8	Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential. Cellular and Molecular Life Sciences, 2014, 71, 3173-3185.	5.4	45
9	Structural dissection of cyclin dependent kinases regulation and protein recognition properties. Cell Cycle, 2010, 9, 1551-1561.	2.6	41
10	The "Gatekeeper―Residue Influences the Mode of Binding of Acetyl Indoles to Bromodomains. Journal of Medicinal Chemistry, 2016, 59, 3087-3097.	6.4	36
11	GroEL from the psychrophilic bacterium Pseudoalteromonas haloplanktis TAC 125: molecular characterization and gene cloning. Extremophiles, 2003, 7, 17-28.	2.3	33
12	Inhibitor affinity chromatography: Profiling the specific reactivity of the proteome with immobilized molecules. Proteomics, 2003, 3, 1287-1298.	2.2	33
13	Structural and functional analysis of the flexible regions of the catalytic α-subunit of protein kinase CK2. Journal of Structural Biology, 2012, 177, 382-391.	2.8	32
14	High-Throughput Fragment Docking into the BAZ2B Bromodomain: Efficient <i>in Silico</i> Screening for X-Ray Crystallography. ACS Chemical Biology, 2016, 11, 800-807.	3.4	32
15	Pharmacological inactivation of the prion protein by targeting a folding intermediate. Communications Biology, 2021, 4, 62.	4.4	30
16	Active Form of the Protein Kinase CK2 \hat{l} ± $<$ sub $>$ 2 $<$ /sub $>$ \hat{l} 2 $<$ sub $>$ 2 $<$ /sub $>$ Holoenzyme Is a Strong Complex with Symmetric Architecture. ACS Chemical Biology, 2014, 9, 366-371.	3.4	29
17	Screening Approaches for Targeting Ribonucleoprotein Complexes: A New Dimension for Drug Discovery. SLAS Discovery, 2019, 24, 314-331.	2.7	29
18	Structural and functional determinants of protein kinase CK2α: facts and open questions. Molecular and Cellular Biochemistry, 2011, 356, 67-73.	3.1	28

#	Article	IF	CITATIONS
19	An Inhibitor's-Eye View of the ATP-Binding Site of CDKs in Different Regulatory States. ACS Chemical Biology, 2014, 9, 1251-1256.	3.4	27
20	The STAS domain of mammalian SLC26A5 prestin harbours an anion-binding site. Biochemical Journal, 2016, 473, 365-370.	3.7	24
21	Different orientations of low-molecular-weight fragments in the binding pocket of a BRD4 bromodomain. Acta Crystallographica Section D: Biological Crystallography, 2013, 69, 2161-2164.	2.5	23
22	Derivatives of 3-Amino-2-methylpyridine as BAZ2B Bromodomain Ligands: In Silico Discovery and in Crystallo Validation. Journal of Medicinal Chemistry, 2016, 59, 9919-9927.	6.4	23
23	Recognition of Cdk2 by Cdk7. Proteins: Structure, Function and Bioinformatics, 2007, 67, 1048-1059.	2.6	21
24	Discovery of BAZ2A bromodomain ligands. European Journal of Medicinal Chemistry, 2017, 139, 564-572.	5.5	21
25	Discovery of Inhibitors of Four Bromodomains by Fragment-Anchored Ligand Docking. Journal of Chemical Information and Modeling, 2017, 57, 2584-2597.	5.4	21
26	Binding to DNA of the RNA-polymerase II C-terminal domain allows discrimination between Cdk7 and Cdk9 phosphorylation. Nucleic Acids Research, 2008, 37, 1260-1268.	14.5	18
27	Characterization of the oligomeric states of the CK2 $\hat{l}\pm2\hat{l}^2$ 2 holoenzyme in solution. Biochemical Journal, 2017, 474, 2405-2416.	3.7	17
28	A novel class of selective CK2 inhibitors targeting its open hinge conformation. European Journal of Medicinal Chemistry, 2020, 195, 112267.	5.5	15
29	Structure and single crystal spectroscopy of Green Fluorescent Proteins. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2011, 1814, 824-833.	2.3	12
30	Structural Analysis of Smallâ€Molecule Binding to the BAZ2A and BAZ2B Bromodomains. ChemMedChem, 2018, 13, 1479-1487.	3.2	11
31	Identification of compounds inhibiting prion replication and toxicity by removing PrP ^C from the cell surface. Journal of Neurochemistry, 2020, 152, 136-150.	3.9	11
32	The lysine-specific demethylase 1 is a novel substrate of protein kinase CK2. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 722-729.	2.3	9
33	Biochemical and cellular mechanism of protein kinase CK2 inhibition by deceptive curcumin. FEBS Journal, 2020, 287, 1850-1864.	4.7	9
34	Inhibitory Properties of ATP-Competitive Coumestrol and Boldine Are Correlated to Different Modulations of CK2 Flexibility. Journal of Natural Products, 2019, 82, 1014-1018.	3.0	4
35	Insight into GFPmut2 pH Dependence by Single Crystal Microspectrophotometry and X-ray Crystallography. Journal of Physical Chemistry B, 2018, 122, 11326-11337.	2.6	3
36	Identification of a BAZ2A Bromodomain Hit Compound by Fragment Joining. ACS Bio & Med Chem Au, 2021, 1, 5-10.	3.7	3

ARTICLE IF CITATIONS

37 Structural Basis of CK2 Regulation by Autoinhibitory Oligomerization., 2015,, 35-47.